Last reviewed · How we verify
Pembrolizuma
Pembrolizuma, marketed by Memorial Sloan Kettering Cancer Center, is an advanced therapy for patients with advanced or recurrent cervical cancer. The drug's key strength lies in its mechanism of action, which targets the disease effectively, positioning it as a significant player in this therapeutic area. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Pembrolizuma |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Target | Programmed cell death protein 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Advanced or recurrent cervical cancer
- Classical Hodgkin lymphoma
- Endometrial carcinoma progressing after chemotherapy
- HER2-negative breast cancer
- Malignant tumor of head and/or neck
- Metastatic malignant melanoma
- Metastatic renal cell carcinoma
- Microsatellite instability-high colorectal cancer
- Non-small cell lung cancer
- Squamous cell carcinoma of esophagus
- Triple negative breast neoplasms
- Unresectable urothelial carcinoma
Common side effects
- Nausea
- Fatigue
- Musculoskeletal pain
Key clinical trials
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer (PHASE1, PHASE2)
- A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |